Emma Walmsley, GlaxoSmithKline CEO (Mandel Ngan/AFP via Getty Images)

Sting­ing from a proxy loss and hun­gry for cash, Glax­o­SmithK­line bails on eq­ui­ty stake in In­no­vi­va for a tidy $392M

Fol­low­ing a failed at­tempt to chal­lenge a slate of new board can­di­dates at a com­pa­ny in which it’s a sig­nif­i­cant mi­nor­i­ty share­hold­er, Glax­o­SmithK­line has sold off its en­tire eq­ui­ty stake.

GSK last week at­tempt­ed to thwart the elec­tion of five pro­posed board mem­bers at the an­nu­al meet­ing of Burlingame, CA-based In­no­vi­va, the biotech said in an SEC fil­ing Thurs­day, ob­ject­ing to all but one of the new can­di­dates. Then lat­er Thurs­day, GSK an­nounced it had sold its en­tire 32% stake in In­no­vi­va, rais­ing about $392 mil­lion.

The Big Phar­ma said in a press re­lease the sale would help fund its plans to split in­to two com­pa­nies some­time next year. It wasn’t clear if GSK’s sale was a di­rect re­sponse to los­ing the chal­lenge or why they ob­ject­ed, and a GSK spokesper­son de­clined to com­ment.

Ac­cord­ing to In­no­vi­va, near­ly all of the votes against those five board can­di­dates came from GSK’s shares. Each of the five re­ceived about 45.8 to 48 mil­lion votes in fa­vor and 35.9 to 38 mil­lion votes against. GSK had con­trolled about 32 mil­lion shares.

Among the board mem­bers up for elec­tion in­clud­ed for­mer No­var­tis CFO George Bick­er­staff and Deb­o­rah Birx, the Trump ad­min­is­tra­tion’s coro­n­avirus re­sponse co­or­di­na­tor. Birx was the on­ly pro­posed board mem­ber to which GSK did not ob­ject.

The sale rep­re­sents the lat­est move in a con­tin­u­ing dance be­tween GSK, In­no­vi­va and the lat­ter’s for­mer par­ent com­pa­ny, Ther­a­vance Bio­phar­ma, the San Fran­cis­co Busi­ness Times re­port­ed. For­mer­ly just known as Ther­a­vance, In­no­vi­va spun out from the com­pa­ny back in 2014. Ther­a­vance fo­cus­es now on drug de­vel­op­ment, while In­no­vi­va col­lects roy­al­ties from sev­er­al GSK-brand­ed El­lip­ta in­haler prod­ucts.

Over the last few years, Ther­a­vance and In­no­vi­va have gone to court over how In­no­vi­va planned to in­vest the roy­al­ties. Ther­a­vance ar­gued the cash was go­ing to be fun­neled back to share­hold­ers, while In­no­vi­va said it planned to in­vest some of the mon­ey in­to oth­er com­pa­nies. GSK, Ther­a­vance’s largest share­hold­er, backed the com­pa­ny in court.

In late March, an ar­bi­tra­tor ruled in fa­vor of In­no­vi­va, say­ing the com­pa­ny had not vi­o­lat­ed its agree­ment with Ther­a­vance.

As part of Thurs­day’s sale, In­no­vi­va plans to dis­trib­ute $110 mil­lion to one of its sub­sidiaries in or­der to fund the pur­chase, the com­pa­ny said. The sub­sidiary is a biotech and health care fund ad­vised by Saris­sa Cap­i­tal Man­age­ment, a hedge fund that en­gaged in an ac­tivist at­tack on In­no­vi­va back in 2018. In­no­vi­va’s CEO, Pavel Raifeld, is a for­mer Saris­sa in­vestor who be­gan his cur­rent po­si­tion last May.

For GSK, the res­pi­ra­to­ry col­lab­o­ra­tion with In­no­vi­va re­mains un­changed. GSK is ex­pect­ed to an­nounce fur­ther plans re­gard­ing its split next month, Reuters re­ports, and CEO Em­ma Walm­s­ley said af­ter a dis­ap­point­ing earn­ings re­port in April plans for the sep­a­ra­tion are “well un­der­way.”

Mar­ket­ingRx roundup: Pfiz­er de­buts Pre­vnar 20 TV ads; Lil­ly gets first FDA 2022 pro­mo slap down let­ter

Pfizer debuted its first TV ad for its Prevnar 20 next-generation pneumococcal pneumonia vaccine. In the 60-second spot, several people (actor portrayals) with their ages listed as 65 or older are shown walking into a clinic as they turn to say they’re getting vaccinated with Prevnar 20 because they’re at risk.

The update to Pfizer’s blockbuster Prevnar 13 vaccine was approved in June, and as its name suggests is a vaccine for 20 serotypes — the original 13 plus seven more that cause pneumococcal disease. Pfizer used to spend heavily on TV ads to promote Prevnar 13 in 2018 and 2019 but cut back its TV budgets in the past two fall and winter seasonal spending cycles. Prevnar had been Pfizer’s top-selling drug, notching sales of just under $6 billion in 2020, and was the world’s top-selling vaccine before the Covid-19 vaccines came to market last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla (Photo by Steven Ferdman/Getty Images)

UP­DAT­ED: Pfiz­er fields a CRL for a $295M rare dis­ease play, giv­ing ri­val a big head start

Pfizer won’t be adding a new rare disease drug to the franchise club — for now, anyway.

The pharma giant put out word that their FDA application for the growth hormone therapy somatrogon got the regulatory heave-ho, though they didn’t even hint at a reason for the CRL. Following standard operating procedure, Pfizer said in a terse missive that they would be working with regulators on a followup.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Graphic: Alexander Lefterov for Endpoints News

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

Of the countless decisions Vlad Coric had to make as Biohaven’s CEO over the past seven years, there was one that felt particularly nerve-wracking: Instead of selling to a Big Pharma, the company decided it would commercialize its migraine drug itself.

“I remember some investors yelling and pounding on the table like, you can’t do this. What are you thinking? You’re going to get crushed by AbbVie,” he recalled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Alexander Lefterov/Endpoints News

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

Bob Seibert sat silent across from his daughter at their favorite Spanish restaurant near his home in Charleston County, SC, their paella growing cold as he read through all the places in his body doctors found tumors.

He had texted his wife, a pediatric intensive care nurse, when he got the alert that his online chart was ready. Although he saw immediately it was bad, many of the terms — peritoneal, right iliac — were inscrutable. But she was five hours downstate, at a loud group dinner the night before another daughter’s cheer competition.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Not cheap­er by the dozen: Bris­tol My­ers be­comes the 12th phar­ma com­pa­ny to re­strict 340B sales

Bristol Myers Squibb recently joined 11 of its peer pharma companies in limiting how many contract pharmacies can access certain drugs discounted by a federal program known as 340B.

Bristol Myers is just the latest in a series of high-profile pharma companies moving in their own direction as the Biden administration’s Health Resources and Services Administration struggles to rein in the drug discount program for the neediest Americans.

Joaquin Duato, J&J CEO (Photo by Charles Sykes/Invision/AP)

New J&J CEO Joaquin Du­a­to promis­es an ag­gres­sive M&A hunt in quest to grow phar­ma sales

Joaquin Duato stepped away from the sideline and directly into the spotlight on Tuesday, delivering his first quarterly review for J&J as its newly-tapped CEO after an 11-year run in senior posts. And he had some mixed financial news to deliver today while laying claim to a string of blockbuster drugs in the making and outlining an appetite for small and medium-sized M&A deals.

Duato also didn’t exactly shun large buyouts when asked about the future of the company’s medtech business — where they look to be in either the top or number 2 position in every segment they’re in — even though the bar for getting those deals done is so much higher.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Amgen's Twitter campaign #DearAsthma inspired thousands of people to express struggles and frustrations with the disease

Am­gen’s #Dear­Asth­ma spon­sored tweet lands big on game day, spark­ing thou­sands to re­spond

Amgen wanted to know how people with asthma really felt about daily life with the disease. So it bought a promoted tweet on Twitter noting the not-so-simple realities of life with asthma and ended the post with a #DearAsthma hashtag, a megaphone emoji and a re-tweet button.

That was just over one week ago and the responses haven’t stopped. More than 7,000 posts so far on Twitter replied to #DearAsthma to detail struggles of daily life, expressing humor, frustration and sometimes anger. More than a few f-bombs have been typed or gif-ed in reply to communicate just how much many people “hate” the disease.

Pfiz­er, Bris­tol My­ers dom­i­nate top 10 pre­dic­tions for the best-sell­ing drugs of 2022

The annual exercise where analysts try and predict which drugs will become blockbusters and make the most money tends to highlight the biggest trends in biopharma R&D. 2022 is no exception.

The team at Evaluate Vantage published its predictions for the top 10 selling drugs for the year — expecting tens of billions of dollars in sales and highlighting an industry-wide focus on certain diseases and indications.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Nabiha Saklayen, Cellino co-founder and CEO (via Cellino)

Backed by Bay­er's Leaps, Boston-based Celli­no lands $80M for cell ther­a­py-in-box

The summer before Cellino CEO and co-founder Nabiha Saklayen started at Harvard, she lost her grandmother following complications to diabetes. Before then, she hadn’t taken a biology class since ninth or tenth grade — the mark of a classic physicist — but it was then she decided she wanted the rest to sit at the intersection of the two for the rest of her career

Combine that with being across the way from the University’s stem cell institute in Cambridge, and you get the birth of Cellino, an autonomous cell therapy manufacturing company that just announced the closing of its Series A.